Volume 35, Issue 4 (July 2024)                   Studies in Medical Sciences 2024, 35(4): 250-264 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Karimi Babaahmadi M, Mohajeri Iravani M, Orandi A, Orandi A, Fallah E, Fattah Ghazi S, et al . COMPARING THE EFFECTIVENESS AND SAFETY OF CASIRIVIMAB/IMDEVIMAB WITH BAMLANIVIMAB IN PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS. Studies in Medical Sciences 2024; 35 (4) :250-264
URL: http://umj.umsu.ac.ir/article-1-6232-en.html
Assistant Professor, Pain Anesthesiology, Department of Anesthesiology, School of Medicine, Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran (Corresponding Author) , saeed.khorramnia@gmail.com
Abstract:   (954 Views)
Background & Aims: Casirivimab/imdevimab and bamlanivimab are monoclonal antibodies that are used in the treatment of patients with COVID-19. The aim of the present study was to compare the effectiveness and safety of the casirivimab/imdevimab versus bamlanivimab in COVID-19 patients through a systematic review and meta-analysis.
Materials & Methods: A systematic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science databases to identify relevant articles up to March 2024. Moreover, a manual search was performed in the sources of primary review and key studies. There was no restriction on the language of the studies. The risk of bias of the studies was conducted using the ROBINS-I tool. Data analysis was performed using Review Manager Software version 5.4.
Results: A total of 10 observational studies involving 10695 patients were included in the study. The results of the meta-analysis showed that casirivimab/imdevimab significantly reduced the hospitalization rate compared to bamlanivimab (odds ratio [OR]: 0.56, %95, 0.40-0.79, P<0.001). However, there was no significant difference between casirivimab/imdevimab and bamlanivimab groups in terms of mortality rate (OR: 0.53, %95, 0.25-1.13, P=0.10), emergency department visit (OR: 0.91, %95, 0.71-1.17, P=0.48), ICU admission (OR: 0.65, %95, 0.33-1.26, P=0.20), mechanical ventilation (OR: 0.28, %95, 0.05-1.54, P=0.14) and adverse events (OR: 0.44, %95, 0.15-1.34, P=0.15).
Conclusion: The results of this meta-analysis showed that there is no difference between casirivimab/imdevimab and bamlanivimab in terms of clinical effectiveness and safety. However, casirivimab/imdevimab has better effectiveness compared to bamlanivimab in reducing hospitalization rates in the patients with COVID-19.

 
Full-Text [PDF 691 kb]   (378 Downloads)    
Type of Study: Review article | Subject: عفونی

References
1. Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population-based study. Lancet Reg Health West Pac 2023;40. [DOI:10.1016/j.lanwpc.2023.100928]
2. Franchini M, Focosi D, Cruciani M, Joyner MJ, Pirofski L-a, Senefeld JW, et al. Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis. Diseases 2024;12(3):41. [DOI:10.3390/diseases12030041]
3. Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immun Inflamm Dis 2022;10(6):e628. [DOI:10.1002/iid3.628]
4. Zaboli Mahdiabadi M, Karami C, Saber E, Kamali M, Orandi A, Dadashi A, et al. Effectiveness of Molnupiravir in the Treatment of Patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;33(12):857-67. [DOI:10.61186/umj.33.12.857]
5. Sharififar S, Dadashi A, Orandi A, Shiri Malekabad E, Khorramnia S, Alazmani Noodeh F. Efficacy and Safety of Favipiravir in Patients with COVID-19: A Review of Systematic Reviews and Meta-Analysis. Stud Med Sci 2022;32(10):782-92. [DOI:10.52547/umj.32.10.782]
6. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: a review. Front Med 2020;7:480. [DOI:10.3389/fmed.2020.00480]
7. Amani B, Akbarzadeh A, Amani B, Shabestan R, Khorramnia S, Navidi Z, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A Systematic Review and MetaAnalysis. J Med Virol 2023;95(6):e28889. [DOI:10.1002/jmv.28889]
8. Khorramnia S, Navidi Z, Orandi A, Iravani MM, Orandi A, Malekabad ES, et al. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Clin Transplant Res 2024;38(2):136-44. [DOI:10.4285/ctr.24.0015]
9. Lai C-C, Chen S-Y, Ko W-C, Hsueh P-R. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents 2021;57(4):106324. [DOI:10.1016/j.ijantimicag.2021.106324]
10. Ahorsu DK, Lin C-Y. The effect of COVID-19 vaccine acceptance, intention, and/or hesitancy and its association with our health and/or important areas of functioning. MDPI; 2023. p. 368. [DOI:10.3390/vaccines11020368]
11. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22(9):1293-302. [DOI:10.1016/S1473-3099(22)00320-6]
12. Atanasov V, Barreto N, Whittle J, Meurer J, Weston BW, Luo Q, et al. Understanding COVID-19 Vaccine Effectiveness against Death Using a Novel Measure: COVID Excess Mortality Percentage. Vaccines 2023;11(2):379. [DOI:10.3390/vaccines11020379]
13. Yan Z, Yang M, Lai C-L. COVID-19 vaccinations: a comprehensive review of their safety and efficacy in special populations. Vaccines 2021;9(10):1097. [DOI:10.3390/vaccines9101097]
14. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health 2020;8(8):e1003-e17. [DOI:10.1016/S2214-109X(20)30264-3]
15. Stadler E, Burgess MT, Schlub TE, Khan SR, Chai KL, McQuilten ZK, et al. Monoclonal antibody levels and protection from COVID-19. Nat Commun 2023;14(1):4545. [DOI:10.1038/s41467-023-40204-1]
16. van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv 2023;7(11):2645-55. [DOI:10.1182/bloodadvances.2022009578]
17. Cimellaro A, Addesi D, Cavallo M, Spagnolo F, Suraci E, Cordaro R, et al. Monoclonal antibodies and antivirals against SARS-CoV-2 reduce the risk of long COVID: a retrospective propensity score-matched case-control study. Biomedicines 2022;10(12):3135. [DOI:10.3390/biomedicines10123135]
18. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020;369(6506):1010-4. [DOI:10.1126/science.abd0827]
19. Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther 2021;10(4):2479-88. [DOI:10.1007/s40121-021-00525-4]
20. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021;384(3):229-37. [DOI:10.1056/NEJMoa2029849]
21. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med 2021;13(593):eabf1906. [Google Scholar]
22. Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19. Open Forum Infect Dis 2021;8(7):ofab331. [DOI:10.1093/ofid/ofab331]
23. Farcy DA, Dalley MT, Miro G, Swalley P, Sherman D, Nash J, et al. A comparison of SARS-COV-2 neutralizing antibody therapies in high-risk patients with mild to moderate COVID-19 disease at a single academic hospital. J Emerg Med 2022;62(1):83-91. [DOI:10.1016/j.jemermed.2021.07.025]
24. McCreary EK, Bariola JR, Minnier TE, Wadas RJ, Shovel JA, Albin D, et al. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. Contemp Clin Trials 2022;119:106822. [DOI:10.1016/j.cct.2022.106822]
25. Balasubramanian P, Berto CG, Hassan E, Valentine N, De Vos G, Coyle C, et al. Outcomes in Patients with Mild COVID-19 Treated With Casirivimab and Imdevimab or Bamlanivimab-A Single-Center Retrospective Cohort Study in the Bronx. Infect Dis Clin Pract 2022;30(3):e1128. [DOI:10.1097/IPC.0000000000001128]
26. Chilimuri S, Mantri N, Gurjar H, Youthjug KA, Sun H, Gongati S, et al. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: a South-Bronx experience. J Nat Med Assoc 2022;113(6):701-5. [DOI:10.1016/j.jnma.2021.08.036]
27. Cooper MH, Christensen PA, Salazar E, Perez KK, Graviss EA, Nguyen D, et al., editors. Real-world assessment of 2879 COVID-19 patients treated with monoclonal antibody therapy: a propensity score-matched cohort study. Open Forum Infect Dis 2021;8(11): ofab512. [DOI:10.1093/ofid/ofab512]
28. Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, et al. Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019. J Infect Dis 2021;224(8):1278-86. [DOI:10.1093/infdis/jiab377]
29. San Filippo S, Crovetto B, Bucek J, Nahass RG, Milano M, Brunetti L. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis. Open Forum Infect Dis 2022;9(4):ofac080. [DOI:10.1093/ofid/ofac080]
30. Savoldi A, Morra M, De Nardo P, Cattelan AM, Mirandola M, Manfrin V, et al. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Eur J Clin Microbiol Infect Dis 2022;41(7):1065-76. [DOI:10.1007/s10096-022-04464-x]
31. Voelker D, Jerath M. Monoclonal antibody infusion for COVID-19 infection: results from a tertiary referral center. J Allergy Clin Immunol 2022;149(2):AB194. [DOI:10.1016/j.jaci.2021.12.639]
32. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021;184(9):2316-31. [DOI:10.1016/j.cell.2021.03.029]
33. Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: A Systematic Review and Network Meta-Analysis. Infection 2023;51(1):21-35. [DOI:10.1007/s15010-022-01825-8]
34. Amani B, Khodavirdilou L, Rajabkhah K, Moghaddam VK, Akbarzadeh A, Amani B. Efficacy and safety of bamlanivimab in patients with COVID-19: A Systematic Review and Meta-Analysis. World J Virol 2024;13(1). [DOI:10.5501/wjv.v13.i1.88660]
35. Orandi A, Mohajeri M, Mansouri M, Salajegheh M, Jalili M, Esmaiil Zali M, et al. Clinical Effectiveness of Casirivimab and Imdevimab Compared with Standard of Care in COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2024;34(11):727-41. [DOI:10.61186/umj.34.11.8]
36. Khorramnia S, Jalili M, Salajegheh M, Mansouri M. Efficacy of Bamlanivimab Compared to Standard Care in Treatment of the Patients with COVID-19: A Systematic Review and Meta-Analysis. Stud Med Sci 2023;34(8):461-70. [DOI:10.61186/umj.34.8.461]
37. Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, et al. A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2. Infect Dis Ther 2021;10(4):1933-47. [DOI:10.1007/s40121-021-00515-6]
38. Wicaksono IA, Suhandi C, Elamin KM, Wathoni N. Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial. Heliyon 2023. [DOI:10.1016/j.heliyon.2023.e22839]
39. Gao M, Ao G, Hao X, Xie B. Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19: A systematic review with meta-analysis. J Infect 2023;87(1):82. [DOI:10.1016/j.jinf.2023.04.019]
40. Tai Y-L, Lee M-D, Chi H, Chiu N-C, Lei W-T, Weng S-L, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ 2023;11:e15344. [DOI:10.7717/peerj.15344]
41. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: a systematic review and meta‐analysis of randomized controlled trials. J Med Virol 2022;94(5):2222-9. [DOI:10.1002/jmv.27623]
42. Zuo L, Ao G, Wang Y, Gao M, Qi X. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: a systematic review and meta-analysis. J Infect 2022;84(2):248. [DOI:10.1016/j.jinf.2021.09.003]
43. Hwang Y-C, Lu R-M, Su S-C, Chiang P-Y, Ko S-H, Ke F-Y, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci 2022;29(1):1. [DOI:10.1186/s12929-021-00784-w]
44. Siemieniuk RA, Bartoszko JJ, Martinez JPD, Kum E, Qasim A, Zeraatkar D, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Br Med J 2021;374. [Google Scholar]
45. McConnell D, Harte M, Walsh C, Murphy D, Nichol A, Barry M, et al. Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. Sci Rep 2022;12(1):17561. [DOI:10.1038/s41598-022-22431-6]
46. Plichta J, Kuna P, Panek M. Monoclonal antibodies as potential COVID-19 therapeutic agents. COVID 2022;2(5):599-620. [DOI:10.3390/covid2050045]
47. Taylor PC, Adams AC, Hufford MM, De La Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 2021;21(6):382-93. [DOI:10.1038/s41577-021-00542-x]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb